Enforcement in the Pharmaceutical Industry Michael K. Loucks First Assistant U.S. Attorney United States Attorney’s Office District of Massachusetts October.

Slides:



Advertisements
Similar presentations
Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.
Advertisements

An Overview of Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Risk Communication Advisory Committee May 15, 2008.
Erica J. Bailey, A.A.G. Chief of Civil Investigations
“Medication Units” (Opioid Treatment Programs) Drug Enforcement Administration James “Jim” Arnold Chief, Policy Unit Office of Diversion Control D E A.
MEAT LABELING IN SOUTH AFRICA PRESENTATION ANDISA POTWANA: DIRECTOR: CONSUMER LAW AND POLICY 26 MARCH 2013.
Substantiation of Health Claims in Advertising: Probiotics Richard L. Cleland Division of Advertising Practices Federal Trade Commission.
Public Health Issues Related to Mutually Conforming Labeling: CDRH Perspective Miriam C. Provost, Ph.D. Office of Device Evaluation Center for Devices.
The United States False Claims Act Qui Tam Whistleblower Law Getnick & Getnick LLP | Counsellors At Law Rockefeller Center, 620 Fifth Avenue | New York,
Endorsement Split Dollar Plans Reward & retain key executives ©2014 Voya Services Company. All rights reserved. CN
Pharmaceutical and Health Care Association of the Philippines vs. Health Secretary Francisco T. Duque III et al.
25-1 Chapter 44 Consumer Protection and Product Safety.
RAC Study Group Chapter 16
FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.
May 13, 2005 North Carolina State University Off-Label Use and Product Liability: Basic Principles David L. Baumer, Ph.D., J.D., Attorney at Law, Professor.
Cross-Labeling: Legal and Regulatory Issues David M. Fox Hogan & Hartson LLP th Street, NW Washington, DC
 2011 Johns Hopkins Bloomberg School of Public Health Regulation of Tobacco Products Mitch Zeller, JD Pinney Associates.
Consumer Protection Agencies Introduction to Business & Marketing.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
Certification of Accounts. Certification of accounts » Audit Report on Financial (Attest) Audit is about expression of Auditor’s Opinion on the Financial.
Pharmacy and Therapeutics Committee
Regulation of Drug Marketing Introduction to Drug Law and Regulation FDLI Workshop April 28-29, 2003 Teaneck, New Jersey Philip Katz Crowell & Moring LLP.
Regulations Relating to Foodstuffs for Infants and Young Children (Foodstuffs, Cosmetics and Disinfectants Act, 1972) Briefing to the Portfolio Committee.
Special Issues in FDA-Regulated Studies: The Good, the Bad, and the Ugly C. Karen Jeans, MSN, CCRN, CIP COACH Program Analyst VA Office of Research & Development.
The Regulatory Authority for Off-Label Promotion
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
MEDICAL DEVICE PROSECUTIONS AND ENFORCEMENT TRENDS IN THE HEALTH CARE INDUSTRY Michael K. Loucks First Assistant U.S. Attorney United States Attorney’s.
20__ Fredrikson & Byron P.A A Practical Path -- Does the First Amendment Matter? Presented by Bob Klepinski
Investigational New Drug Application (IND)
When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.
INDs : Does My Study Need One? Edith Paal UAMS Office of Research Compliance August 22, 2003.
Sales and Marketing in the Pharmaceutical Industry: At the Vortex of the Perfect Legal Storm Paul E. Kalb, M.D., J.D. Princeton, N.J. - June 7, 2004.
Overview of FDA's Regulatory Compliance Agenda Daniel Meron, Esq. General Counsel Department of Health and Human Services August 22, 2007.
Latham & Watkins operates as a limited liability partnership worldwide with affiliated limited liability partnerships conducting the practice in the United.
Presented by J F Luterek, Pr.Eng Hahn & Hahn Attorneys
ACCESS TO MEDICINES - POLICY AND ISSUES
KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.
BTEC ICT Legal Issues Data Protection Act (1998) Computer Misuse Act (1990) Freedom of Information Act (2000)
CHAPTER 8 Consumer Relations.
FDLI Introduction to Medical Device Law and Regulation Other Postmarket Controls Philip Katz (202) October 29, 2002 Washington,
Center for Drug Evaluation and Research (CDER) Tanya Eberle Kamal Diar David Clements.
Discount Medical Plan Organizations (DMPOs) David Foy Florida Office of Insurance Regulation January 25, 2006.
© 2010 Pearson Education, Inc., publishing as Prentice-Hall 1 CONSUMER PROTECTION AND PRODUCT SAFETY © 2010 Pearson Education, Inc., publishing as Prentice-Hall.
Investigational Devices and Humanitarian Use Devices June 2007.
National Medical Device Audioconference: How the Recent Landmark $311 Million Device Settlements Will Change Industry Practices Insights Into Federal Investigations.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
1/29/ Ask Matt - November 2011 – FERPA – Surveillance Video and Emergencies Matt Carver, J.D., Director of Legal Services tel fax.
FDA, Labeling, and Marketing
Chapter Dental Public Health & Research Contemporary Practice for the Dental Hygienist Copyright ©2011 by Pearson Education, Inc. All rights reserved.
Promotion of Prescription Drugs and Biologics Thomas O. Henteleff Kleinfeld, Kaplan and Becker LLP Company logo here.
BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. Reprints.
FDA Draft Guidance Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved.
Presenting Truthful Information to Doctors Aaron S. Kesselheim, M.D., J.D. Brigham and Women ’ s Hospital Harvard School of Public Health Boston, Massachusetts.
Off Label Use in Managed Care Pharmacy Presentation Developed for the Academy of Managed Care Pharmacy Updated February 2015.
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
Lessons Learned from Federal Prosecutions Michael K. Loucks First Assistant U.S. Attorney District of Massachusetts.
Section 6.1 Government and Laws Chapter 6 legal and ethical issues Section 6.2 Social Responsibilities and Ethics.
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
Washington Legal Foundation Advocate for Freedom and Justice ® WLF Balancing the Public's Right to Know With the Government's Obligation to Protect Patients.
How to Put Together an IDE Application
Action Items: Monitoring Off-Label Promotion Do’s and Don’t’s
PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.
DOJ Pharmaceutical Prosecutions
Off-Label Liability: Legal and Compliance Issues
DRAFT FOR DISCUSSION Promotion Prohibitions under the Cannabis Act Health Canada, Cannabis Legalization and Regulation Branch September 2018.
Generic Medical Device Company (“MDC”)
Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.
Opening an IND: Investigator Perspective
Regulatory Perspective of the Use of EHRs in RCTs
2006 PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS NOVEMBER 9,2006
A FRIENDLY REMINDER ON OTC DRUGS. DRUG REGULATIONS IN THE PHILIPPINES.
Presentation transcript:

Enforcement in the Pharmaceutical Industry Michael K. Loucks First Assistant U.S. Attorney United States Attorney’s Office District of Massachusetts October 2008 Views expressed are speaker’s personal opinions

Drug Industry Cases Years Total Recoveries PharmaCases% ,600,000171,000, ,602,040,776274,440, June ,407,609,4045,742,282, Totals15,866,250,1806,187,722, Source: Loucks and Lam, Prosecuting and Defending Health Care Fraud Cases, 2007 Cumulative Supplement, Chapter 11 (BNABooks.com)

Off Label Promotion TAP Prosecution, 2001: TAP Prosecution, 2001: –Not an off-label case –Two components: kickbacks, best price Parke Davis Prosecution, 2004: Parke Davis Prosecution, 2004: –First major drug industry off-label case –Not the first off-label prosecution of an FDA regulated product Majority of pending investigations involve off-label promotion allegations Majority of pending investigations involve off-label promotion allegations No end in sight No end in sight

Labeling Claims made to sell product –whether in promotional pieces, statements made by sales reps, advertisements, must be consistent with approved labeling. 21 C.F.R (e)(4). Claims made to sell product –whether in promotional pieces, statements made by sales reps, advertisements, must be consistent with approved labeling. 21 C.F.R (e)(4). Off-label claims include both unapproved indications and claims about product that exceed statements on the label Off-label claims include both unapproved indications and claims about product that exceed statements on the label

Intended Use: 21 CFR The intent is determined by such persons' expressions or may be shown by the circumstances surrounding the distribution of the article. This objective intent may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives. It may be shown by the circumstances that the article is, with the knowledge of such persons or their representatives, offered and used for a purpose for which it is neither labeled nor advertised. The intent is determined by such persons' expressions or may be shown by the circumstances surrounding the distribution of the article. This objective intent may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives. It may be shown by the circumstances that the article is, with the knowledge of such persons or their representatives, offered and used for a purpose for which it is neither labeled nor advertised.

Intended Use But if a manufacturer knows, or has knowledge of facts that would give him notice that a device introduced … by him is to be used for conditions, purposes, or uses other than the ones for which he offers it, he is required to provide adequate labeling for such a device which accords with such other uses to which the article is to be put. But if a manufacturer knows, or has knowledge of facts that would give him notice that a device introduced … by him is to be used for conditions, purposes, or uses other than the ones for which he offers it, he is required to provide adequate labeling for such a device which accords with such other uses to which the article is to be put. Section 352 provides that a drug is misbranded if it does not contain adequate directions for use Section 352 provides that a drug is misbranded if it does not contain adequate directions for use

“Promotion” Law does not define nor prohibit certain types of promotional activities Law does not define nor prohibit certain types of promotional activities Law prohibits distribution with intent to distribute the product for uses that are not approved: to distribute a misbranded product or an adulterated product Law prohibits distribution with intent to distribute the product for uses that are not approved: to distribute a misbranded product or an adulterated product Examples Examples –product with no approvals –Product with one approval

Free Speech v. Off-Label Promotion No free speech right to promote a device for an off-label use No free speech right to promote a device for an off-label use –There is a tension between the “exchange of reliable scientific data and information within the health care community and the statutory requirements that prohibit companies from promoting products for unapproved uses.” Virginia Bd. Of Pharmacy v. Virginia Citizens Consumer Counil, inc., 425 U.S. 748, 765 (1976). Virginia Bd. Of Pharmacy v. Virginia Citizens Consumer Counil, inc., 425 U.S. 748, 765 (1976).

Off-Label Promotion Government has a substantial interest in the regulation of medical devices and in “subjecting off-label uses to the FDA’s evaluation process.” Government has a substantial interest in the regulation of medical devices and in “subjecting off-label uses to the FDA’s evaluation process.” “[P]ermitting defendants to engage in all forms of truthful, non-misleading promotion of off-label uses would severly frustrate the FDA’s ability to evaluate the effectiveness of off-label uses.” “[P]ermitting defendants to engage in all forms of truthful, non-misleading promotion of off-label uses would severly frustrate the FDA’s ability to evaluate the effectiveness of off-label uses.” –United States v. Caputo, 288 F. Supp. 2d 912 (N.D.Ill. 2003).

Schering Example Intron A approved, treatment of numerous conditions, but not superficial bladder cancer Intron A approved, treatment of numerous conditions, but not superficial bladder cancer –The label contained no directions for use for that indication –Sales reps engaged in wide spread marketing for that indication Hypothetical question often posed: Why can’t those reps engage in truthful dissemination about information regarding that drug’s use in treating that cancer? Hypothetical question often posed: Why can’t those reps engage in truthful dissemination about information regarding that drug’s use in treating that cancer?

Not the issue Speech, by itself, is not the issue Speech, by itself, is not the issue Crime: distribution of product intending that it be used for an indication, where the label does not provide adequate directions for use in treating that condition Crime: distribution of product intending that it be used for an indication, where the label does not provide adequate directions for use in treating that condition The speech becomes a part of our proof of the criminal conduct The speech becomes a part of our proof of the criminal conduct

Example “Bank X has a bank branch on Main Street and every Tuesday morning at 8:00 a.m., the armored car company makes a delivery of six bags.” “Bank X has a bank branch on Main Street and every Tuesday morning at 8:00 a.m., the armored car company makes a delivery of six bags.” –Truthful statement –Factually accurate Protected speech or evidence of a crime? Protected speech or evidence of a crime?

Impact on sales and marketing Sales activity dependant on “marketplaces”: Sales activity dependant on “marketplaces”: –The person/entity using, prescribing, or controlling use: a doctor, a nursing home administrator a doctor, a nursing home administrator –The person/entity paying for the product or in whose budget the item falls: the retail patient; HMO management, the pharmacy department of a hospital, the benefits administrator the retail patient; HMO management, the pharmacy department of a hospital, the benefits administrator –The person or entity controlling access: E.g., P & T committee for a hospital; the P & T committee of a bellwether hospital; medical director of a dialysis facility E.g., P & T committee for a hospital; the P & T committee of a bellwether hospital; medical director of a dialysis facility

Relevance The marketplace at issue affects the sales activity and the legal relevance of that activity: The marketplace at issue affects the sales activity and the legal relevance of that activity: –Sales activity is willful: deliberately engaged in with a targeted purpose –Must be funded: budget must be prepared, presented, reviewed, approved –Is monitored for success: has the targeted purpose been satisfied –Is modified to meet changes in the marketplace